about
Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancerMesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3Recent progress in pancreatic cancerMesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy.Genetic engineering of T cells for adoptive immunotherapyIdentification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesotheliomaMesothelin expression in the leptomeninges and meningiomasMesothelin targeted cancer immunotherapyMesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumorsClinical impacts of mesothelin expression in gastrointestinal carcinomasEnvironmental carcinogenesis - 100th anniversary of creating cancerNew insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomasAntigen-specific immunotherapy of cervical and ovarian cancerRecognition of Mesothelin by the Therapeutic Antibody MORAb-009: STRUCTURAL AND MECHANISTIC INSIGHTSSelecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane ProteinsSerum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancersMesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathwayAberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cellsA multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomasMannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibodyEffect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical modelNew high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesotheliomaGene expression changes are age-dependent and lobe-specific in the brown Norway rat model of prostatic hyperplasiaEstablishment of a novel specific ELISA system for rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesotheliomaProteomics and biomarkers in clinical trials for drug developmentA novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity.New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8.Pancreatic cancer.Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types.Human antibodies for immunotherapy development generated via a human B cell hybridoma technology.Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells.Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodiesMesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats.A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptakePathogenesis of ovarian cancer: clues from selected overexpressed genes.What's the place of immunotherapy in malignant mesothelioma treatments?Biological approaches to therapy of pancreatic cancer.Megakaryocytic potentiating factor and mature mesothelin stimulate the growth of a lung cancer cell line in the peritoneal cavity of mice.Origin of myofibroblasts in the fibrotic liver in mice
P2860
Q24622837-5C061F7D-7A4F-4154-B65B-28C5B9B5C7FBQ24622968-00B8E41B-2C64-4DEB-8008-94136035D2DAQ24626346-8FA50AB2-A1D9-4AB5-8523-8720203F85A8Q24642374-F1EEC303-292E-4E31-94E0-40F7096FFCF1Q24642718-0B617A29-875B-4008-83E6-44D0C5778A76Q24646373-6CF0B36F-5DC3-43DA-BE47-DD7F1B5B5883Q24654033-713EA894-BDF1-4410-8261-BC32372A0205Q24656242-272C83D5-1173-431E-8BC3-90C44DACEC75Q24673454-6558DEE3-6C95-45C8-8EA7-146FEA848BA0Q26748680-6F2FF21D-415B-4024-BE0C-4953E8031526Q26796683-A220BA10-4109-4261-AC5B-2257BF2A2CB5Q26859274-477DCA6E-0C65-4D7A-AA77-EC5282ED078DQ27488697-3EC675A9-1D25-4BBF-92E4-74A08B500916Q27670713-E40D010C-2E56-4F11-BD9A-E6BE46A196D5Q28077999-2287922B-9FBE-4ABF-90F3-766C53C9E6ADQ28254804-DCDD9090-6E81-4AA0-A113-B86E9CE46AD8Q28258206-8994C13D-EC37-4C17-931A-987B6D395B69Q28263206-D21B0FE2-016D-4B40-9020-F973E75F37A3Q28392105-A222CF4C-CEAF-4D3F-B5B4-FDD27EC8221FQ28478285-291E8569-18F2-4663-B22B-A26F0AB8F025Q28544295-488E82CE-CC35-4C41-BF68-2DC0BECACB57Q28547381-132B89B6-8132-4CDA-A380-3938354F0F83Q28570394-C302D4DA-25C8-4BB9-9938-3190C244A0B5Q28570727-E152B65A-1C6C-4FFA-A95D-FBCD22FFEE06Q30402667-B1ED3219-8E50-49AE-BFFD-0147325D0CA6Q30478956-B3F95C1A-C913-4793-A45E-A5149A234081Q30489770-84793D64-62CA-4C78-96BA-063D4B75AFD9Q30490247-07591FC5-7C38-4215-A228-A95C4A625F47Q30980266-86281D66-4F4F-4509-90BC-31F7F9630325Q33234976-8C12A3CE-B64B-4900-84CA-A771AA7CCD0DQ33297414-2B8850C0-DEF2-4AF2-8821-4F809C6DA857Q33311571-6F44BC0B-4930-41AE-AA01-744D8590FC5FQ33322420-83F27BFC-1F1F-4AF4-855A-2376BB7370DEQ33398152-F5898A10-36EF-4D2A-8785-C567498DE13CQ33639027-4701899E-1B5F-4B65-B3A4-9AEC3CE8BFEAQ33651139-11194330-8057-440B-AC03-5CCA07238AEEQ33781142-5A96820F-C17B-4D48-AF57-DA1B6F23C868Q33899938-4BD44D86-1D0D-4A73-AE2A-A83F12A79577Q34042096-BF54CE37-14BA-42E3-A64B-430002C38819Q34060761-BCC6B15D-E6CD-45C5-B307-3F54C4DDBFB5
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Mesothelin: a new target for immunotherapy
@ast
Mesothelin: a new target for immunotherapy
@en
Mesothelin: a new target for immunotherapy
@nl
type
label
Mesothelin: a new target for immunotherapy
@ast
Mesothelin: a new target for immunotherapy
@en
Mesothelin: a new target for immunotherapy
@nl
prefLabel
Mesothelin: a new target for immunotherapy
@ast
Mesothelin: a new target for immunotherapy
@en
Mesothelin: a new target for immunotherapy
@nl
P2093
P3181
P1476
Mesothelin: a new target for immunotherapy
@en
P2093
Ira Pastan
Raffit Hassan
Tapan Bera
P304
P3181
P356
10.1158/1078-0432.CCR-03-0801
P407
P433
P577
2004-06-15T00:00:00Z